Searching On:

Drug:

Herceptin

       
View:
Expand Collapse Herceptin  - General Description trastuzumab
A recombinant humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2). After binding to HER2 on the tumor cell surface, trastuzumab induces an antibody-dependent cell-mediated cytotoxicity against tumor cells that overexpress HER2. HER2 is overexpressed by many adenocarcinomas, particularly breast adenocarcinomas..
Drug Code Name
ABP 980
PF-05280014
RO0452317
Drug Short Name
MOAB HER2
rhuMAb HER22
Synonyms
anti-c-erB-2
anti-c-erbB2 monoclonal antibody
anti-ERB-2
anti-erbB-2
anti-erbB2 monoclonal antibody
anti-HER2/c-erbB2 monoclonal antibody
anti-p185-HER2
Herceptin biosimilar PF-05280014
Herceptin trastuzumab biosimilar PF-05280014
MOAB HER2
monoclonal antibody c-erb-2
monoclonal antibody HER2
trastuzumab biosimilar ABP 980
trastuzumab biosimilar HLX02
trastuzumab biosimilar PF-05280014
trastuzumab biosimilar SB3
US Brand Names
Herceptin
Ogivri
trastuzumab
A recombinant humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2). After binding to HER2 on the tumor cell surface, trastuzumab induces an antibody-dependent cell-mediated cytotoxicity against tumor cells that overexpress HER2. HER2 is overexpressed by many adenocarcinomas, particularly breast adenocarcinomas..
Drug Code Name
ABP 980
PF-05280014
RO0452317
Drug Short Name
MOAB HER2
rhuMAb HER22
Synonyms
anti-c-erB-2
anti-c-erbB2 monoclonal antibody
anti-ERB-2
anti-erbB-2
anti-erbB2 monoclonal antibody
anti-HER2/c-erbB2 monoclonal antibody
anti-p185-HER2
Herceptin biosimilar PF-05280014
Herceptin trastuzumab biosimilar PF-05280014
MOAB HER2
monoclonal antibody c-erb-2
monoclonal antibody HER2
trastuzumab biosimilar ABP 980
trastuzumab biosimilar HLX02
trastuzumab biosimilar PF-05280014
trastuzumab biosimilar SB3
US Brand Names
Herceptin
Ogivri

Share with your Physican

Print information for your Physician.

Print information

Your Matched Clinical Trials

Trial Matches: (D) - Drug
Trial Status: Showing all 6 results Per Page:
Protocol # Title Location Status Match
NCT02390427 Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer MGH Open D
NCT02465060 Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) MGH Open D
NCT03013218 A Study of ALX148 in Patients With Advanced Solid Tumors and Lymphoma A Study of ALX148 in Patients With Advanced Solid Tumors and Lymphoma MGH Open D
NCT03043313 Tucatinib (ONT-380) and Trastuzumab in Treating Patients With HER2+ Metastatic Colorectal Cancer Tucatinib (ONT-380) and Trastuzumab in Treating Patients With HER2+ Metastatic Colorectal Cancer MGH Open D
NCT03587740 ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer MGH Open D
NCT03716180 DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC MGH Open D
MGH has many open clinical trials for other cancers not shown on the Targeted Cancer Care website. They can be found on the MassGeneral.org clinical trials search page.

Additional clinical trials may be applicable to your search criteria, but they may not be available at MGH. These clinical trials can typically be found by searching the clinicaltrials.gov website.
Trial Status: Showing all 6 results Per Page:

Share with your Physican

Print information for your Physician.

Print information